#United States #New York #Securities Fraud #Pomerantz LLP #PepGen Inc

Investigation of PepGen Inc. by Pomerantz Law Firm

Pomerantz LLP, a prominent law firm renowned for its focus on investor rights, is currently investigating potential claims on behalf of shareholders of PepGen Inc. (NASDAQ: PEPG). The firm aims to determine if there have been any instances of securities fraud or unlawful practices carried out by PepGen and its officers or directors. This investigation arises in light of pressing concerns among investors, particularly following alarming developments related to the company's clinical trials.

Recent Press Release and Market Reaction

On December 16, 2024, PepGen publicly disclosed a clinical hold notice issued by the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug application for the CONNECT2-EDO51 clinical trial, which targets patients suffering from Duchenne muscular dystrophy (DMD). The statement from the FDA indicated that an official clinical hold letter would be provided within 30 days. This unexpected news had immediate consequences, causing PepGen's stock to drop by $0.17 per share, translating to a steep decline of 3.63%, closing at $4.51 that same day.

The Importance of Investor Awareness

With such significant fluctuations in stock prices, the role of law firms like Pomerantz becomes critical in protecting investors' interests. The investigation aims to assess whether the actions of PepGen's management compromised the company’s integrity or could have exposed its shareholders to undue financial risks. Investors who may have experienced losses or feel misled are encouraged to contact Pomerantz LLP for more information regarding their legal options.

About Pomerantz LLP

Established over 85 years ago by the late Abraham L. Pomerantz, who is often referred to as the dean of the class action bar, the firm is recognized for pioneering efforts in securities class actions. Pomerantz LLP is headquartered in New York and has additional offices in major cities such as Chicago, Los Angeles, London, Paris, and Tel Aviv. This significant footprint enhances their capabilities to address complex cases involving corporate misconduct or breaches of fiduciary duty.

The firm has a storied history of recovering substantial damages on behalf of investors through class action litigation. Their dedication to fighting for shareholders empowers numerous investors potentially harmed by fraudulent corporate actions.

Next Steps for Investors

Investors affected by recent developments concerning PepGen Inc. should take proactive steps to understand their rights. Pomerantz LLP encourages affected shareholders to reach out for legal consultation and guidance. Interested parties can contact attorney Danielle Peyton directly via email or phone for further discussion about joining the class action suit.

As the investigation unfolds, it remains crucial for investors to remain informed and vigilant about the treatment and disclosure of critical information by companies in which they hold shares. Keeping abreast of potential legal recourse may prove invaluable for securing their financial interests moving forward.

For those who believe they've encountered issues related to PepGen’s recent disclosures or operations, Pomerantz is prepared to assist in navigating the complexities of securities litigation. More details can be found by visiting their website or contacting their office directly.